News

May 6, 2022

Allorion Therapeutics presents preclinical data supporting the development of its TYK2 inhibitor at the IMMUNOLOGY2022 meeting


Allorion Therapeutics named ARTS-011 as the development candidate for its TYK2 program. The preclinical data for ARTS-011 will be presented on May 7 in a poster session at the American Association of Immunologists (AAI) Annual Meeting 2022 in Portland, Oregon.

Read More


April 8, 2022

Allorion Therapeutics presents preclinical data supporting the development of its CDK2 inhibitor at the AACR Annual Meeting 2022


Allorion Therapeutics named ARTS-021 as the development candidate for its CDK2 program. The preclinical data for ARTS-021 will be presented on April 12 in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, Louisiana.

Read More


ENDPOINTS NEWS | November 23, 2021

A fledgling transpacific biotech grabs a launch round to dive into oncology and autoimmune research


Precision-med biotech Allorion Therapeutics is expanding — and now has tens of millions of dollars more to work with.

In the Media


November 23, 2021

Allorion Therapeutics announces $40 million series A financing


Allorion Therapeutics, a company focusing on next-generation precision medicine for oncology and autoimmune disease, today announced the completion of $40M Series A financing.

Read More


December 1, 2020

Allorion Therapeutics builds internal laboratories


Allorion Therapeutics established laboratories at our Natick and Guangzhou sites and put them into operation, enabling us to carry out biological and chemical experiments in-house. Together with our contract research organizations, these internal experimental facilities will further strengthen our R&D capabilities.